The Center draws upon the expertise of a wide range of investigators with complementary interests in diabetes, obesity, inflammation, lipid metabolism and atherosclerosis. Members of the Center’s faculty conduct both basic research to clarify the mechanisms causing diabetes and obesity and their consequences, and translational research to transform their research findings into clinical solutions.
Two-thirds of the adult U.S. population is overweight and one-half of those individuals – one-third of the adult population – are obese. The prevalence of type 2 diabetes (formerly known as “adult-onset”) has also increased markedly in recent decades not only among adults, but in children as well. Although type 1 diabetes is less common, it is a potentially devastating disorder affecting both children and adults and, while treatments for both types of diabetes exist, neither is curable and effective treatments for obesity have yet to be developed.
Much of the good we accomplish is made possible by private support: by people and organizations underwriting leading-edge research and providing funding to train promising fellows. With your help, the DOCE is improving lives throughout the Northwest and around the world.
Dr. Christiane Hampe has received a one year pilot research award through the T1D Exchange Biobank Operations Center at the Benaroya Research Institute (BRI)
Dr. Christiane Hampe has received an award from the National Ataxia Foundation for her project entitled Glutamate Decarboxylase in Cerebellar Ataxia.
Dr. Michael Schwartz is author of a recent editorial entitled Can the History of Modern Endocrinology Shape the Future of Obesity?
Letters of Intent are due by January 5, 2015 and the deadline for applications is February 23, 2015.
Dr. Michael Schwartz has been listed as one of the most highly influential biomedical researchers in the paper entitled “A list of highly influential biomedical researchers, 1996-2011″
Dr. Christiane Hampe is co-author on the article “Antibodies to islet cell autoantigens, rotaviruses and/or enteroviruses in cord blood and healthy mothers in relation to the 2010–2011 winter viral seasons in Israel: a pilot study” published in Diabetic Medicine.
Dr. Michael Schwartz is featured in an interview by the American Society for Clinical Investigation (ASCI), published on September 10, 2014.
Dr. Joshua Thaler is one of 5 recipients awarded a Pathway to Stop Diabetes Accelerator Award from the American Diabetes Association. This 5-year, $1.625 million grant entitled ” Modulating glial-neuronal interactions to treat obesity and diabetes” explores the possibility that glial cells (the brain’s damage response cells) in the hypothalamus area of the brain play an important part in the process of becoming obese and developing diabetes.
Dr. Michael Schwartz has been awarded a 4-year NIH R01 for his project ” Novel Brain Mechanisms Controlling Glucose Homeostasis”. This project is based upon recently published evidence from the Schwartz Laboratory that the brain can rapidly, potently and selectively increase insulin-independent glucose lowering.
DOCE Director Michael Schwartz, MD, has been selected to give the 7th Annual Levi J. Hammond Distinguished Memorial Lecture. This annual lecture was held at the University of Pennsylvania on May 13, 2014.…
DOCE Director Michael Schwartz, MD, is senior author on a review article published in the May issue of Nature Review Neuroscience. The article entitled “Neurobiology of food intake in health and disease…” highlights how the interplay between homeostatic and emergency feeding circuits influences the biologically defended level of body weight under physiological and pathophysiological conditions.